TRCT
MPLT

Tower Research Capital (TRC)’s MapLight Therapeutics MPLT Stock Holding History

Tower Research Capital (TRC)’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2K Sell
1,928
-942
-33% -$16.9K ﹤0.01% 2961
2025
Q4 		$50.4K Buy
+2,870
New +$48.1K ﹤0.01% 2407

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s MPLT Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its MapLight Therapeutics (MPLT) stake by 33% in Q1 2026, selling an estimated $16.9K and leaving 1,928 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2961.

Tower Research Capital (TRC) first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. The position peaked at $50.4K in Q4 2025. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Tower Research Capital (TRC) held 1,928 shares of MapLight Therapeutics worth $39.2K as of Q1 2026.
  • Tower Research Capital (TRC) sold 942 MapLight Therapeutics shares in Q1 2026, an estimated $16.9K.
  • MapLight Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2961 holding.
  • Tower Research Capital (TRC) first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Tower Research Capital (TRC)'s MapLight Therapeutics position peaked at $50.4K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.